FLT3

ESH 2019 | How will the use of FLT3 inhibitors evolve in the future?

L:

The AML Global Portal were delighted to speak to Alexander Perl, University of Pennsylvania, Philadelphia, US, during the European School of Hematology (ESH) Translational Research Conference on AML. We asked Alexander Perl: How will the use of FLT3 inhibitors evolve in the future? He describes the clinical use of FLT3 inhibitors in the relapsed/refractory setting.

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF
Was this article informative? Thank you for your feedback!